Pregled bibliografske jedinice broj: 1235026
New prospects in treatment of dyslipidaemia – putting patient compliance first
New prospects in treatment of dyslipidaemia – putting patient compliance first // 14. kongres Hrvatskoga kardiološkog društva ; 9. kongres Hrvatske udruge kardioloških medicinskih sestara = 14th Congress of the Croatian Cardiac Society ; 9th Congress of the Croatian Association of Cardiology Nurses
Zagreb, Hrvatska: Medicinska naklada, 2022. str. 279-279 doi:10.15836/ccar2022.279 (poster, recenziran, sažetak, stručni)
CROSBI ID: 1235026 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
New prospects in treatment of dyslipidaemia –
putting patient compliance first
Autori
Strikić, Dominik ; Slišković, Ana Marija ; Vujević, Andro ; Sopek-Merkaš, Ivana ; Merćep, Iveta
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Skup
14. kongres Hrvatskoga kardiološkog društva ; 9. kongres Hrvatske udruge kardioloških medicinskih sestara = 14th Congress of the Croatian Cardiac Society ; 9th Congress of the Croatian Association of Cardiology Nurses
Mjesto i datum
Zagreb, Hrvatska, 24.11.2022. - 27.11.2022
Vrsta sudjelovanja
Poster
Vrsta recenzije
Recenziran
Ključne riječi
dyslipidaemia, statins, inclisiran, PCSK9 inhibitors, patient compliance
Sažetak
Dyslipidaemia is one of the leading cardiovascular risk factors. For a long time, successful treatment options were used, with statin therapy being the cornerstone. Nowadays, more and more new agents are being discovered and approved for the treatment of dyslipidaemia. This summary provides a brief overview of newly approved drugs and those still in development.
Izvorni jezik
Engleski
